2016•Mayo Clinic ProceedingsOpen access

Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs

Chul Kim, Vinay K. Prasad

Open full text 127 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 127 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Surrogate endpoint, Medicine, Food and drug administration, Drug approval, Clinical endpoint, Overall survival, Internal medicine, Correlation

Back to paper search Browse research topics Original source

Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs — Research Paper | ScholarLens